Cardiol Therapeutics Inc. Weighted Average Fair Value At Measurement Date Share Options Granted
Cardiol Therapeutics Inc. (CRDL) had Weighted Average Fair Value At Measurement Date Share Options Granted of CAD 0.86 as of 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Notes
ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted · last filed 2026-03-31
- 2022-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted $1.34.
- 2021-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted $2.33.
- 2020-12-31: Weighted Average Fair Value At Measurement Date Share Options Granted $1.52.
USD
| Period end | Weighted Average Fair Value At Measurement Date Share Options Granted |
|---|---|
| 2022-12-31 | $1.34 20-F · filed 2023-03-29 |
| 2021-12-31 | $2.33 20-F · filed 2023-03-29 |
| 2020-12-31 | $1.52 20-F · filed 2023-03-29 |
CAD
| Period end | Weighted Average Fair Value At Measurement Date Share Options Granted |
|---|---|
| 2025-12-31 | 0.86 CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 1.77 CAD 40-F · filed 2026-03-31 |
| 2023-12-31 | 0.64 CAD 40-F · filed 2025-03-31 |
| 2022-12-31 | 1.34 CAD 20-F · filed 2024-04-01 |
| 2021-12-31 | 2.33 CAD 20-F · filed 2024-04-01 |